• Pam3CSK4 (SKU A9920): Reliable TLR1/2 Agonist for Immune Ass

  2026-05-11

  This article explores real-world laboratory challenges in immune cell activation and inflammation modeling, demonstrating how Pam3CSK4 (SKU A9920) delivers robust, reproducible results. Integrating scenario-driven Q&A, protocol guidelines, and comparative analysis, it highlights why Pam3CSK4 is a trusted choice for TLR1/2 pathway studies.

• Calpeptin: Calpain Inhibitor Workflows for Fibrosis Research

  2026-05-10

  Calpeptin enables precision modulation of calpain-driven pathways, delivering nanomolar potency in both cellular and animal models of fibrosis and inflammation. This guide breaks down experimental workflows, troubleshooting strategies, and evidence-based best practices for researchers optimizing calpain inhibition in translational studies.

• Hetero-Galactan from S. vaninii Targets TLR4/NF-κB for Lipid

  2026-05-09

  This study reports the structural characterization and hypolipidemic effects of a novel hetero-galactan (SVP3) from Sanghuangporus vaninii. SVP3 acts by modulating the TLR4/NF-κB pathway, reducing lipid accumulation, inflammation, and hepatic injury in a mouse model, highlighting its potential as a low-toxicity therapeutic lead for hyperlipidemia.

• Ferroptosis-Related Gene Signature and Atorvastatin in HCC P

  2026-05-08

  This study introduces a novel prognostic model based on ferroptosis-related genes for hepatocellular carcinoma (HCC), identifying Atorvastatin as a candidate agent capable of inducing ferroptosis and inhibiting HCC cell growth and migration. The findings support the integration of ferroptosis modulation and HMG-CoA reductase inhibition in liver cancer research, with practical implications for experimental design and therapeutic development.

• Liproxstatin-1: Expanding Ferroptosis Inhibitor Utility Beyo

  2026-05-08

  Explore how Liproxstatin-1, a potent ferroptosis inhibitor, enables new frontiers in oxidative stress and glandular dysfunction research. This article offers a deep dive into unique mechanisms, assay considerations, and translational implications distinct from standard renal or cancer models.

• ECL Chemiluminescent Substrate Detection Kit: Pushing Bounda

  2026-05-07

  Explore how the ECL Chemiluminescent Substrate Detection Kit (Hypersensitive) enables advanced horseradish peroxidase (HRP) chemiluminescence and sets new standards in low-abundance protein analysis. Dive deeper into practical assay optimization and translational insights not found in other reviews.

• Advanced Strategies with ECL Chemiluminescent Substrate Dete

  2026-05-07

  Explore how the ECL Chemiluminescent Substrate Detection Kit empowers ultra-sensitive, low-background immunoblotting. This article uniquely bridges mechanistic insights from tumor metabolism research to practical assay optimization, offering evidence-based guidance for HRP chemiluminescence workflows.

• FCCP in Immunometabolic Reprogramming: Precision, Insight, a

  2026-05-06

  This thought-leadership article explores how FCCP (carbonyl cyanide p-trifluoromethoxyphenylhydrazone) is redefining mitochondrial biology and immunometabolic research. By synthesizing mechanistic insights, recent breakthrough findings on macrophage metabolic education, and actionable protocol guidance, we provide translational researchers with a strategic roadmap for leveraging FCCP to dissect tumor hypoxia, immune evasion, and metabolic regulation. The discussion draws on leading literature—including the latest discoveries in lysosomal AMPK activation—and situates APExBIO FCCP as the essential tool for high-impact studies.

• Thioredoxin System Regulates CHK1 Inhibitor Response in NSCL

  2026-05-06

  This study reveals that the thioredoxin (Trx) antioxidant system is a critical determinant of non-small cell lung cancer (NSCLC) cell sensitivity to CHK1 inhibitors via redox-mediated control of ribonucleotide reductase (RNR) activity. The findings highlight a mechanistic link between cellular redox regulation and DNA precursor synthesis, providing a rational basis for combination strategies to overcome CHK1 inhibitor resistance and minimize toxicity.

• QNZ (EVP4593): Applied Protocols for NF-κB Pathway Modulatio

  2026-05-05

  QNZ (EVP4593) empowers precise and reproducible NF-κB signaling pathway studies, with proven efficacy in both inflammatory and neurodegenerative disease models. This article delivers actionable protocols, troubleshooting strategies, and data-backed optimization tips to maximize performance in advanced research workflows.

• JHU-083: Applied Protocols for Glutaminase Pathway Research

  2026-05-05

  JHU-083, a 6-diazo-5-oxo-L-norleucine precursor, enables targeted glutaminase inhibition in neurological and experimental cerebral malaria models. This guide details optimized protocols, troubleshooting strategies, and insights from recent oxidative stress research to maximize experimental success.

• circ_0042103/TAF15/NER Axis Links Circular RNA to DNA Damage

  2026-05-04

  This study uncovers a novel circ_0042103/TAF15/NER regulatory axis driving DNA damage and inflammation in dental pulpitis. By mechanistically connecting circular RNA regulation with impaired DNA repair, the work advances our understanding of inflammatory disease progression and highlights new molecular targets for tissue regeneration.

• Oligo (dT) 25 Beads: Technical Guidance for mRNA Isolation

  2026-05-04

  Oligo (dT) 25 Beads address the need for rapid, highly specific eukaryotic mRNA isolation by leveraging magnetic bead-based polyA tail capture. They are best suited for workflows requiring intact mRNA for downstream applications such as RT-PCR and next-generation sequencing. These beads are not recommended when non-polyadenylated RNA species are required or for workflows incompatible with magnetic separation.

• PA-824: Bicyclic Nitroimidazole Derivative in TB Research

  2026-05-03

  PA-824 empowers anti-tuberculosis research with its potent, dual-action mechanism and high-purity formulation, enabling reproducible inhibition of both drug-sensitive and drug-resistant Mycobacterium tuberculosis strains. This article details experimental workflows, advanced use-cases, and troubleshooting strategies that maximize the translational impact of this trusted APExBIO compound.

• Aneugen Mechanism Assay: Molecular Targets and Microtubule D

  2026-05-02

  This article reviews a proof-of-concept bioassay that differentiates aneugenic mechanisms by analyzing the effects of 27 chemicals, including microtubule-associated inhibitors, on mammalian cell models. The work advances the field by coupling flow cytometry with machine learning to resolve tubulin-specific actions from mitotic kinase inhibition, providing a robust framework for mechanistic genotoxicity assessment.

15837 records 9/1056 page Previous Next First page 上5页 678910 下5页 Last page